Top Markets
#1 ADO Protocol ADO Protocol +328.85%
#2 Tutorial Tutorial +56.73%
#3 GoPlus Security GoPlus Security +53.03%
#4 Nockchain Nockchain +49.31%
#5 The Black Bull The Black Bull +36.28%
#6 Starpower Starpower +34.09%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +29.52%
#8 GAIB AID GAIB AID +24.67%
#9 Casper Network Casper Network +17.01%
#10 Verus Coin Verus Coin +16.19%
Coin of the day
ADO Protocol ADO Protocol
Settings
Language
ENGLISH
Currency
USD
Theme
Traws Pharma, Inc. Traws Pharma, Inc.

Traws Pharma, Inc.

TRAW
Rank in Stocks #33162
Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage,... Traws Pharma, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to creating novel small-molecule medications delivered orally to combat both respiratory viral infections and various forms of cancer. Its pipeline includes experimental treatments specifically designed to overcome drug resistance in influenza and COVID-19. These promising candidates include TRX01 (travatrelvir), an Mpro/3CL inhibitor currently undergoing development for COVID-19, and TRX100 (viroxavir), an endonuclease inhibitor advancing through trials for pandemic influenza. Additionally, Traws Pharma's oncology portfolio features narazaciclib, a multi-kinase CDK4/6 inhibitor. This compound is presently in Phase 1/2 clinical trials in cancer patients, being evaluated both independently and in conjunction with letrozole, with the goal of establishing the recommended Phase 2 dosage for future work in endometrial cancer. The company is also investigating oral rigosertib, exploring its potential as a standalone therapy or in combination regimens across diverse cancer types. Originally established in 1998 as Onconova Therapeutics, Inc., the company officially adopted its current name, Traws Pharma, Inc., in April 2024. Its corporate headquarters are located in Newtown, Pennsylvania.
Share Price
$0.55
Market Cap
$8.38M
Change (1 day)
-3.68%
Change (1 year)
-63.58%
Country
US
Trade Traws Pharma, Inc. (TRAW)

Category

Healthcare
Operating Margin for Traws Pharma, Inc. (TRAW)
Operating Margin as of 2026 TTM: 0.00%
According to Traws Pharma, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Traws Pharma, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.